IM Cannabis Secures Funding through Private Placement
IM Cannabis Corp. (NASDAQ: IMCC) has successfully closed a private placement, generating approximately US$4.1 million in gross proceeds. This strategic offering involved the issuance of 2,050,000 units, with each unit priced at C$2.7427. The funds raised are intended for various general corporate purposes, including working capital and addressing existing debts.
Structure of the Private Placement
Each unit from the offering comprises one common share or, alternatively, one pre-funded common share warrant in lieu of the common share, along with a common share purchase warrant. Each warrant allows its holder to acquire a common share at an exercise price of C$3.43 for a duration of sixty months from its issuance date. The pre-funded warrants enable the purchase of one common share at C$0.00001, providing investors significant flexibility.
Role of Pure Equity Ltd.
In this offering, Pure Equity Ltd. served as a consultant, aiding the company in navigating the complexities of the private placement. Their involvement highlights the collaborative efforts to ensure the success of this financial endeavor.
Regulatory Compliance
All securities issued under this offering are subject to a four-month hold period, as per Canadian securities laws. These securities cannot be sold or offered in jurisdictions where such actions would be unlawful prior to registration or qualification. Furthermore, the offering is exempt from registration under the U.S. Securities Act.
Company's Future Aspirations
With the proceeds from this private placement, IM Cannabis aims to bolster its operations and market position within the burgeoning international cannabis industry. By leveraging this funding, the company plans to enhance its product offerings and expand its footprint in the competitive medical cannabis market.
About IM Cannabis Corp.
IM Cannabis is a global player in the medical cannabis sector, distributing high-quality cannabis products primarily in Germany and Israel. By building a robust ecosystem supported by established supply chains and innovative approaches to medical cannabis provision, IM Cannabis continues to drive substantial growth within this rapidly evolving industry.
Company Details
The company operates through its subsidiaries, overseeing the importation and distribution of cannabis to medical patients effectively. Their integrated model is designed to ensure safety and quality throughout the supply chain, from cultivation to patient access.
Company Contact:
For more information, interested parties can reach out to:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
a.taranko@imcannabis.de
Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
+972-77-3603504
info@imcannabis.com
Frequently Asked Questions
What is the total amount raised in the private placement?
IM Cannabis raised approximately US$4.1 million through the private placement.
Who acted as the consultant for this offering?
Pure Equity Ltd. provided consulting services during the private placement process.
What is the purpose of the funds raised?
The proceeds are intended for general working capital and to repay existing indebtedness.
How many units were issued in the private placement?
A total of 2,050,000 units were issued at a price of C$2.7427 per unit.
Where is IM Cannabis Corp. primarily operating?
IM Cannabis operates mainly in Germany and Israel, focusing on providing medical cannabis products.
